Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina stock crashed Friday after the DNA sequencer broadly lagged Wall Street's quarterly forecasts and slashed its outlook for the year. The post Illumina, DNA Sequencer, Crashes As Covid, China Hammer Quarterly Results appeared first on Investor's Business Daily.

Illumina, DNA Sequencer, Crashes As Covid, China Hammer Quarterly Results

Illumina Inc (NASDAQ:ILMN) shares are due to plummet on Friday after the gene sequencing company swung to a loss in the second quarter as revenue fell short of expectations and it cut its full-year outlook. Revenue grew 3% year over year to US$1.16bn, up 5% on a constant-currency basis, but lower than the consensus estimate of US$1.22bn.

Illumina swings to loss and cuts growth guidance

Illumina, Inc. (NASDAQ:ILMN ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Francis deSouza - President & Chief Executive Officer Joydeep Goswami - Chief Strategy & Corporate Development Officer, Interim Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Dan Brennan - Cowen Dan Arias - Stifel David Westenberg - Piper Sandler Julia Qin - JPMorgan Tejas Savant - Morgan Stanley Puneet Souda - SVB Securities Kyle Mikson - Canaccord Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Jack Meehan - Nephron Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2022 Illumina Earnings Conference Call. At this time, all participants are in listen-only mode.

Illumina, Inc. (ILMN) CEO Francis deSouza on Q2 2022 Results - Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of -9.52% and 4.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q2 Earnings and Revenues Lag Estimates

Illumina Inc. shares sank more than 22% after hours Thursday after the gene-sequencing company swung to a loss in the second quarter, fell short of revenue expectations and revised its full-year outlook downward.

Illumina stock tanks as gene-sequencing company misses expectations and issues bleak outlook

Revenue of $1.16 billion for Q2 2022, up 3% from Q2 2021, and up 5% on a constant currency basis GAAP diluted loss per share of $(3.40) for Q2 2022, compared to GAAP diluted earnings per share of $1.26 for Q2 2021; GAAP diluted loss per share for Q2 2022 includes $609 million in legal contingencies Non-GAAP diluted earnings per share of $0.57 for Q2 2022, compared to non-GAAP diluted earnings per share of $1.87 for Q2 2021 Expect full year revenue for fiscal year 2022 to grow 4% to 5% from fiscal year 2021, primarily reflecting the ongoing negative impact of foreign exchange rates, customer lab expansion delays, and macroeconomic-driven conservatism around immediate capital and inventory commitments, including in Greater China Expect GAAP diluted loss per share of $(2.93) to $(2.78) for fiscal year 2022 Expect non-GAAP diluted earnings per share of $2.75 to $2.90 for fiscal year 2022 SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced its financial results for the second quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Our second quarter results did not meet our expectations as challenges in a complex macroeconomic environment more than offset the growth we continue to see in sequencing runs on our platforms," said Francis deSouza, Chief Executive Officer.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2022

Just in its latest quarter, ILMN registered a solid 23% bottom-line beat.

Illumina Q2 Preview: 8th Consecutive EPS Beat in Store?

Speakers will outline critical steps needed to achieve health equity SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health. In addition, IGF will host a panel session titled "Making 'Genomics for All' More than a Mantra," on the requirements needed to ensure broader access to genomic health.

Illumina Genomics Forum to Feature Bill Gates and Distinguished Health Leaders Addressing Need for Global Access to Genomics

Intuitive Surgical

They're the undisputed leaders of their markets.

Buying Shares of These 2 Monster Stocks on the Dip Could Be a Genius Move

Recently, Zacks.com users have been paying close attention to Illumina (ILMN). This makes it worthwhile to examine what the stock has in store.

Is Most-Watched Stock Illumina, Inc. (ILMN) Worth Betting on Now?

SAN FRANCISCO--(BUSINESS WIRE)--Illumina Ventures, a healthcare-focused venture firm partnered with Illumina, announces the addition of four new members to its European team.

Illumina Ventures Announces Expansion of its Europe Team

PayPal

Unilever

A couple of these stocks have lost half of their value, just this year.

3 Stocks That Are Trading Near 4-Year Lows

EU antitrust regulators are expected to veto U.S. life sciences firm Illumina's acquisition of biotechnology company Grail, people familiar with the matter said on Wednesday.

Exclusive: EU antitrust regulators likely to block Illumina, Grail deal - sources

DRAGEN™ v4.0 brings greater accuracy, comprehensiveness, and efficiency to genomic analysis than ever before, unlocking the full potential of genomics to improve human health  SAN DIEGO , July 27, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the release of Illumina DRAGEN™ v4.0, its most accurate and comprehensive secondary analysis platform. The new features expand laboratories' abilities to perform analyses in key areas such as oncology, pharmacogenomics (PGx), single-cell sequencing, and population genomics within a single platform.

Illumina Unveils its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities

Illumina has offered rivals royalty-free global licences for some of its patents and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust concerns over its acquisition of Grail, people familiar with the matter said.

Illumina offers patent licences to rivals, patent truce with BGI - sources

Biogen

BIIB vs. ILMN: Which Stock Is the Better Value Option?

BIIB vs. ILMN: Which Stock Should Value Investors Buy Now?

Ford Motor Company

IDEXX Laboratories

Lennar

Netflix

Stanley Black & Decker

Under Armour

These seven S&P 500 stocks to buy have crashed amid 2022's market turmoil and are now set for a swift rebound. The post 7 Wildly Oversold S&P 500 Stocks to Buy Now appeared first on InvestorPlace.

7 Wildly Oversold S&P 500 Stocks to Buy Now

Apple

Amazon

Booking Hlds

Monster Beverage

Monolithic Power Systems

NVIDIA

Regeneron Pharmaceuticals

Tyler Technologies

"Mad Money" host Jim Cramer breaks down some of the best-performing S&P 500 stocks since his show debuted on CNBC more than 17 years ago.

These are 10 of the best-performing stocks since Jim Cramer's 'Mad Money' debuted on TV

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that the NHS-Galleri trial successfully completed enrollment in just over 10 months. The trial, which is the largest-ever study of a multi-cancer early detection (MCED) test, has enrolled 140,000 healthy volunteers aged 50-77 from select regions throughout England who have not had a cancer diagnosis or undergone treatment for cancer in the last thre

Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test

Investors didn't like an unfavorable EU court decision.

Why Illumina Stock Is Tumbling This Week

SAN DIEGO , July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2022 following the close of market on Thursday, August 11, 2022.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, Chief Executive Officer, and Joydeep Goswami, Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022

The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SAN DIEGO , July 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative (SBTi). This includes validation of Illumina's corporate greenhouse gas (GHG) emissions reduction targets by the organization.

Illumina Among First in the World to Receive Approval of Science-Based Net-Zero Target

A court ruling in the European Union (EU) giving Brussels the jurisdiction to investigate life sciences firm Illumina's $8 billion takeover bid of biotech company Grail could set a precedent granting regulators wider oversight of deals regardless of the revenue and other particulars.

EU Court OKs Antitrust Probe Into Illumina's Bid to Acquire Grail

LUXEMBOURG (Reuters) -U.S. life sciences company Illumina on Wednesday lost its challenge against European Union scrutiny of its $8 billion cash-and-stock takeover of Grail, as a top European court agreed the EU antitrust watchdog had the right to do so.

Illumina loses challenge against EU antitrust probe into Grail deal

MENLO PARK, Calif. & ST. LOUIS--(BUSINESS WIRE)--Mercy and GRAIL announced plans to offer Galleri®, GRAIL's multi-cancer early detection (MCED) blood test.

News for Illumina Stock (ILMN)